en · de · es · fr · pt
melanotan-2-notes.peptides5388.com › Blog › Chemistry And Receptor Pharmacology — Common Mistakes

Chemistry And Receptor Pharmacology — Common Mistakes

By Editorial Desk · published 2025-08-12 · last reviewed 2025-09-14 · Blog

afamelanotide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2025-09-14. Numbers and descriptions here follow the published literature rather than marketing material.

Chemistry and Receptor Pharmacology

Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.

Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.

Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.

Origins and Research Status

Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.

Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.

The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.

Melanotan-2 at a glance

PropertyValueNotes
Molecular formulaC50H69N15O9Cyclic heptapeptide, C-terminally amidated
Approximate molecular mass1024 DaMonoisotopic mass of the free peptide
AppearanceWhite to off-white powderTypically supplied as a lyophilised solid
Solubility classSoluble in water and polar solventsAlso dissolves in neutral aqueous buffer
Common synonymsMelanotan II, MT-II, MT-2Described as a melanocortin agonist in early literature

Background and Mechanism of Melanotan-2

Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.

Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.

Related pages on this site

Notes from published material

The president of Serbia and Montenegro (Serbian: Предс(ј)едник Србије и Црне Горе, romanized: Preds(j)ednik Srbije i Crne Gore) was the head of state of Serbia and Montenegro. From its establishment in 1992 until 2003, when the country was reconstituted as a confederacy (state union) via constitutional reform, the head of state was known as the president of the Federal Republic of Yugoslavia (Serbian: Предс(ј)едник Савезне Републике Југославије, romanized: Preds(j)ednik Savezne Republike Jugoslavije). With the constitutional reforms of 2003 and the merging of the offices of head of government and head of state, the full title of the president was President of Serbia and Montenegro and Chairman of the Council of Ministers of Serbia and Montenegro (Serbian: Предс(ј)едник Србије и Црне Горе / Предс(ј)едник Сав(ј)ета министара Србије и Црне Горе). In 2006 the office was abolished as the state union was dissolved, with Serbia and Montenegro becoming independent countries.

=== Metal sulfides === Sulfur reacts with many metals. Electropositive metals give polysulfide salts. Copper, zinc, and silver are attacked by sulfur; see tarnishing. Although many metal sulfides are known, most are prepared by high temperature reactions of the elements. Geoscientists also study the isotopes of metal sulfides in rocks and sediment to study environmental conditions in the Earth's past.

In April 2002, Yosri Fouda of Al Jazeera met al-Qaeda member Khalid Sheikh Mohammed and bin al-Shibh, who were in hiding, and they admitted to him their involvement in the attacks. Mohammed had been an organizer and financier of al-Qaeda's 1993 bombing of the World Trade Center, and he was the uncle of Ramzi Yousef, the lead bomber in that attack. Mohammed and Yousef planned another terrorist attack, the Bojinka plot, for January 1995. Despite its failure, and Yousef's imprisonment by the U.S. afterwards, the plot would influence the later September 11 attacks. The 2004 9/11 Commission Report determined that the animosity that Mohammed, the principal architect of 9/11, felt towards the U.S. had stemmed from his "violent disagreement with U.S. foreign policy favoring Israel."

In Table 5, the approximately $85 billion fine chemical market is subdivided into major applications according to their relevance: fine chemicals for pharmaceuticals, agrochemicals, and specialty chemicals outside life sciences. Furthermore, a distinction is made between captive (in-house) production and merchant market. Pharmaceutical fine chemicals (PFCs) account for two-thirds of the total. Out of the PFC value of $55 billion, about $23 billion (~40%) are traded, and $32 billion (~60%) are the production value of the pharma industry's in-house production. Within life science products, fine chemicals for agro and veterinary drugs follow in importance. The production value for fine chemicals used for specialty chemicals other than pharmaceuticals and agrochemicals is estimated at $15 billion. As the leading specialty chemical companies (Akzo Nobel, Dow, DuPont, Evonik, Chemtura and Mitsubishi) are backward-integrated, the share of in-house production is estimated at 75%, leaving a merchant market of approximately $5 billion.

UIUC Histology Subject 777 Illustration at wku.edu Anatomy photo: Musculoskeletal/muscle/skeletal1/skeletal3 - Comparative Organology at University of California, Davis MedEd at Loyola histo/practical/muscle/hp7-42.html

Sources: en.wikipedia.org

Further detail

In most people with Alport syndrome (about 85%), the condition is inherited in an X-linked pattern, due to mutations in the COL4A5 gene. A condition is considered X-linked if the gene involved in the disorder is located on the X chromosome. In males, who have only one X chromosome, one altered copy of the COL4A5 gene is sufficient to cause severe Alport syndrome, explaining why most affected males eventually develop kidney failure. In females, who have two X chromosomes, a mutation in one copy of the COL4A5 gene usually results in blood in the urine, but most affected females do not develop kidney failure. Alport syndrome can also be inherited in an autosomal recessive pattern if both copies of the COL4A3 or COL4A4 gene, located on chromosome 2, have been mutated. Most often, the parents of a child with an autosomal recessive disorder are not affected but are carriers of one copy of the altered gene. Past descriptions of an autosomal dominant form are now usually categorized as other conditions. Notably, conditions associated with giant platelets and associated with mutations of MYH9 are no longer considered to be Alport variants. However apparent autosomal dominant transmission of disease associated with mutations in COL4A3 and COL4A4 does occur. Clinical utility gene card for: Alport syndrome.

== Personal life == While a model, Larter moved to Los Angeles to pursue acting. In 2002, she moved to New York City for three years. In an interview with Phillymag, she gave reason for the move: I took some time off to define myself outside the pressures of the industry. Part of me really needed to know if this is what I wanted to do with the rest of my life. In January 2005, she went back to living in Los Angeles for a role in Heroes. In December 2007, Larter and her longtime boyfriend, Hayes MacArthur were engaged. They had met on the set of National Lampoon's Homo Erectus. In a 2007 interview with Cosmopolitan, Larter said: "I told my boyfriend after three weeks that I wanted to marry him and that we could do it tomorrow." On August 1, 2009, Larter and MacArthur married at MacArthur's parents' estate in Kennebunkport, Maine. Among the wedding guests was Larter's close friend and fellow actress Amy Smart. Larter and MacArthur purchased a three-story home in the Hollywood Hills for $2.9 million in 2012. During the COVID-19 pandemic, they moved to Sun Valley, Idaho. On July 20, 2010, Larter announced that she and MacArthur were expecting their first child and on the September 10 episode of Late Night with Jimmy Fallon, announced that she was expecting a boy. Larter gave birth to their son in 2010. In August 2014, Larter confirmed that she and MacArthur were expecting their second child that winter and she had a girl in 2015. As of 2013, Larter had two dogs, Jackpot, a German Shepherd and Ella, a Wheaten terrier.

Molybdenum (42Mo) has seven isotopes in nature, with atomic masses of 92, 94-98, and 100. All are stable except 100Mo, which undergoes double beta decay with a half-life of 7.07×1018 years (the shortest known for this mode) to 100Ru. 92Mo and 98Mo are also energetically able to decay in this manner, to zirconium and ruthenium respectively; the others are theoretically stable. There are also a total of 32 synthetic isotopes known, and at least 13 metastable nuclear isomers, ranging in atomic mass from 81 to 119. The isotopes with mass 93 or lower decay by electron capture or positron emission to niobium isotopes (or zirconium after delayed proton emission); those with mass 99 or higher by ordinary beta decay to technetium. The most stable of the former are 93Mo, recently measured to have a half-life around 4800 years, and 90Mo at 5.56 hours. The most stable of the latter is the medically important 99Mo, half-life 65.932 hours, and whose decay leads to the chief isotope of technetium. By far the most stable isomer is 93m1Mo at 6.85 hours, decaying to its ground state.

== History == The Inca were freeze drying potatoes into chuño since the 13th century. The process involved multiple cycles of exposing potatoes to below freezing temperatures on mountain peaks in the Andes during the evening, and squeezing water out and drying them in the sunlight during the day. The Inca people also used the unique climate of the Altiplano to freeze dry meat. The Japanese koya-dofu, freeze-dried tofu, dates to the mid-1500s in Nagano and the 1600s on Mount Koya. These methods are similar but not technically equivalent to the modern process of freeze-drying which requires access to both refrigeration and vacuum systems. Modern freeze drying began as early as 1890 by Richard Altmann who devised a method to freeze dry tissues (either plant or animal), but went virtually unnoticed until the 1930s. In 1909, L. F. Shackell independently created the vacuum chamber by using an electrical pump. No further freeze drying information was documented until Tival in 1927 and Elser in 1934 had patented freeze drying systems with improvements to freezing and condenser steps. A significant turning point for freeze drying occurred during World War II when blood plasma and penicillin were needed to treat the wounded in the field. Because of the lack of refrigerated transport, many serum supplies spoiled before reaching their recipients. The freeze-drying process was developed as a commercial technique that enabled blood plasma and penicillin to be rendered chemically stable and viable without refrigeration.

Sources: en.wikipedia.org

Frequently asked questions

Is melanotan II identical to alpha-melanocyte-stimulating hormone?

No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.

How does melanotan II differ from afamelanotide?

Afamelanotide is the linear analogue [Nle4-D-Phe7]-alpha-MSH, sometimes called melanotan I, while melanotan II is cyclic and carries three further substitutions. The two are distinct molecules and are not interchangeable in analytical testing.

Is the receptor binding profile well established?

Binding to the four melanocortin receptor subtypes is well documented in vitro. The relative contribution of each subtype to whole-body effects in humans is far less certain.

What is melanotan II?

It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.

Network